At the news
? BEARISHIMPACT 6/10 6-K filed Aug 28, 2026 at 09:06 ET
BioNTech announced termination of the Phase 2 trial (BNT122-01) of autogene cevumeran as monotherapy in resected colorectal cancer after a DSMB recommendation citing a numerical overall survival imbalance and futility. The decision follows a prior futility boundary crossing in October 2025. The separate Phase 2 PDAC trial (IMcode003) combining autogene cevumeran with checkpoint inhibition continues unaffected. This is a meaningful pipeline setback for BioNTech's mRNA cancer immunotherapy platform in a key indication, though the company has multiple other oncology programs.
- BioNTech terminated Phase 2 trial BNT122-01 of autogene cevumeran in ctDNA-positive resected Stage II/III colorectal cancer.
- DSMB recommended termination after identifying a numerical imbalance in overall survival between treatment arms; no new safety signals.
- Futility boundary was crossed in October 2025 but DSMB deemed data immature at that time.
- The separate Phase 2 PDAC trial (IMcode003, NCT05968326) evaluating autogene cevumeran in combination with checkpoint inhibition and chemotherapy continues as planned.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access